Skip to main content
SpringerLink
Log in

Hypertension in Chronic Kidney Disease

  • Chapter
  • First Online:
Diabetes and Hypertension

Part of the book series: Contemporary Diabetes ((CDI))

  • 2026 Accesses

Abstract

Hypertension and diabetes are the two significant cardiovascular risk factors that contribute to the development and progression of chronic kidney disease (CKD). Hypertension is present in >50 % of those with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 and the prevalence increases with diminishing eGFR in parallel with the increasing risk for cardiovascular outcomes. Inappropriate activation of the renin–angiotensin system (RAS) and the sympathetic nervous system (SNS) contributes substantially to hypertension in individuals with kidney disease and the high prevalence of CVD. Thereby, intervention with agents that interrupt the RAS and SNS improve not only hypertension but slow the progression and CKD-related CVD morbidity and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 209.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010.

    Google Scholar 

  2. Crews DC, Plantinga LC, Miller ER 3rd, Saran R, Hedgeman E, Saydah SH, et al. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States. Hypertension. 2010;55(5): 1102–9.

    PubMed  CAS  Google Scholar 

  3. 2009 WHO Global Health report. Available at: http://www.who.int/healthinfo/global_burden_disease/en/index.html.

  4. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.

    PubMed  CAS  Google Scholar 

  5. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006;1(1):8–18.

    PubMed  CAS  Google Scholar 

  6. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296(11):1377–84.

    PubMed  CAS  Google Scholar 

  7. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002;61(4):1486–94.

    PubMed  Google Scholar 

  8. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13): 1296–305.

    PubMed  CAS  Google Scholar 

  9. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–69.

    PubMed  Google Scholar 

  10. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–95.

    PubMed  CAS  Google Scholar 

  11. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–63.

    PubMed  Google Scholar 

  12. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol. 2004;15(8):2195–203.

    PubMed  CAS  Google Scholar 

  13. Ix JH, Shlipak MG, Liu HH, Schiller NB, Whooley MA. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. J Am Soc Nephrol. 2003;14(12):3233–8.

    PubMed  Google Scholar 

  14. Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007;167(11):1130–6.

    PubMed  CAS  Google Scholar 

  15. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32(5):853–906.

    PubMed  CAS  Google Scholar 

  16. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4): 244–52.

    PubMed  CAS  Google Scholar 

  17. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ et al. The effect of a lower target blood pressure on the ­progression of kidney disease: long-term follow-up of the modification of diet in renal ­disease study. Ann Intern Med. 2005;142(5):342–51.

    PubMed  Google Scholar 

  18. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–31.

    PubMed  CAS  Google Scholar 

  19. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension. 2005;45(4):811–7.

    PubMed  CAS  Google Scholar 

  20. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999;33(3):507–17.

    PubMed  CAS  Google Scholar 

  21. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998;54(2):561–9.

    PubMed  CAS  Google Scholar 

  22. Li Z, Lacson E Jr, Lowrie EG, Ofsthun NJ, Kuhlmann MK, Lazarus JM, et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis. 2006;48(4):606–15.

    PubMed  Google Scholar 

  23. Agarwal R. Hypertension in chronic kidney disease and dialysis: pathophysiology and management. Cardiol Clin. 2005;23(3):237–48.

    PubMed  Google Scholar 

  24. Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438–44.

    PubMed  CAS  Google Scholar 

  25. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70(7):1318–24.

    PubMed  CAS  Google Scholar 

  26. Tepel M, Hopfenmueller W, Scholze A, Maier A, Zidek W. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant. 2008;23(11):3605–12.

    PubMed  CAS  Google Scholar 

  27. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373(9668):1009–15.

    PubMed  Google Scholar 

  28. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension. 2009;53(5):860–6.

    PubMed  CAS  Google Scholar 

  29. Bangash F, Agarwal R. Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):656–64.

    PubMed  Google Scholar 

  30. Cappuccio FP, Kerry SM, Forbes L, Donald A. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ. 2004;329(7458):145.

    PubMed  Google Scholar 

  31. Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol. 2007;2(6):1228–34.

    PubMed  Google Scholar 

  32. Koomans HA, Roos JC, Dorhout Mees EJ, Delawi IM. Sodium balance in renal failure. A comparison of patients with normal subjects under extremes of sodium intake. Hypertension. 1985;7(5):714–21.

    PubMed  CAS  Google Scholar 

  33. Koomans HA, Geers AB, Boer P, Roos JC, Dorhout Mees EJ. A study on the distribution of body fluids after rapid saline expansion in normal subjects and in patients with renal insufficiency: preferential intravascular deposition in renal failure. Clin Sci (Lond). 1983;64(2):153–60.

    CAS  Google Scholar 

  34. Murphy RJ. The effect of “rice diet” on plasma volume and extracellular fluid space in hypertensive subjects. J Clin Invest. 1950;29(7):912–7.

    PubMed  CAS  Google Scholar 

  35. Watkin DM, Froeb HG, Hatch FT, Gutman AB. Effects of diet in essential hypertension. II. Results with unmodified Kempner rice diet in 50 hospitalized patients. Am J Med. 1950;9(4):441–93.

    PubMed  CAS  Google Scholar 

  36. He FJ, Marciniak M, Visagie E, et al. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertension. 2009;54(3):482–8.

    PubMed  CAS  Google Scholar 

  37. Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA. 1996;275(20):1590–7.

    PubMed  CAS  Google Scholar 

  38. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334(7599):885–8.

    PubMed  Google Scholar 

  39. Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension. 1991;18(1):67–71.

    PubMed  CAS  Google Scholar 

  40. Ruiz-Ortega M, Esteban V, Rupérez M, Sánchez-López E, Rodríguez-Vita J, Carvajal G, et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens. 2006;15(2):159–66.

    PubMed  CAS  Google Scholar 

  41. Esteban V, Lorenzo O, Ruperez M, et al. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol. 2004;15(6):1514–29.

    PubMed  CAS  Google Scholar 

  42. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35(6):881–900.

    PubMed  CAS  Google Scholar 

  43. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15(8): 1983–92.

    PubMed  CAS  Google Scholar 

  44. Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep. 2003;5(1):73–9.

    PubMed  Google Scholar 

  45. Orth SR, Amann K, Strojek K, Ritz E. Sympathetic overactivity and arterial hypertension in renal failure. Nephrol Dial Transplant. 2001;16 Suppl 1:67–9.

    PubMed  Google Scholar 

  46. McGrath BP, Tiller DJ, Bune A, Chalmers JP, Korner PI, Uther JB. Autonomic blockade and the Valsalva maneuver in patients on maintenance hemodialysis: a hemodynamic study. Kidney Int. 1977;12(4):294–302.

    PubMed  CAS  Google Scholar 

  47. Converse Jr RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912–8.

    PubMed  Google Scholar 

  48. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25(4 Pt 2):878–82.

    PubMed  CAS  Google Scholar 

  49. Coladonato JA, Ritz E. Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients. Adv Ren Replace Ther. 2002;9(3):193–9.

    PubMed  Google Scholar 

  50. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007;13(5):397–411.

    PubMed  Google Scholar 

  51. Levin NW, Hoenich NA. Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens. 2001;10(5):563–8.

    PubMed  CAS  Google Scholar 

  52. Goto N, Tominaga Y, Matsuoka S, Sato T, Katayama A, Haba T, et al. Cardiovascular complications caused by advanced secondary hyperparathyroidism in chronic dialysis patients; special focus on dilated cardiomyopathy. Clin Exp Nephrol. 2005;9(2):138–41.

    PubMed  Google Scholar 

  53. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.

    PubMed  CAS  Google Scholar 

  54. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–84.

    PubMed  CAS  Google Scholar 

  55. Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int. 1995;48(3):806–13.

    PubMed  CAS  Google Scholar 

  56. Yamakado M, Umezu M, Nagano M, Tagawa H. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis. Clin Invest Med. 1991;14(6):623–9.

    PubMed  CAS  Google Scholar 

  57. Takahashi K, Totsune K, Imai Y, et al. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci (Lond). 1993;84(1):47–50.

    CAS  Google Scholar 

  58. Kang DH, Yoon KI, Han DS. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Nephrol Dial Transplant. 1998;13(11):2877–83.

    PubMed  CAS  Google Scholar 

  59. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.

    Google Scholar 

  60. Kidney Disease Outcomes Quality Initiative (K⁄DOQI). K⁄DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 suppl 2):S1–290.

    Google Scholar 

  61. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level metaanalysis. Ann Intern Med. 2003;139(4):244–52.

    PubMed  CAS  Google Scholar 

  62. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, Canadian Society of Nephrology, et al. Guidelines for the management of chronic kidney disease. CMAJ. 2008;179(11):1154–62.

    PubMed  Google Scholar 

  63. He FJ, Marciniak M, Visagie E, Markandu ND, Anand V, Dalton RN, et al. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertension. 2009;54(3):482–8.

    PubMed  CAS  Google Scholar 

  64. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high normal blood pressure: the Trials of Hypertension Prevention, phase II: the Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med. 1997;157:657–667.

    Google Scholar 

  65. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant. 1998;13(7):1682–5.

    PubMed  CAS  Google Scholar 

  66. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008;19(5):999–1007.

    PubMed  CAS  Google Scholar 

  67. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: A systematic review and meta-analysis. Kidney Int. 2008;73:19–33.

    PubMed  CAS  Google Scholar 

  68. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(10):1565–74.

    PubMed  Google Scholar 

  69. Beddhu S, Baird BC, Zitterkoph J, Neilson J, Greene T. Physical activity and mortality in chronic kidney disease (NHANES III). Clin J Am Soc Nephrol. 2009;4(12):1901–6.

    PubMed  Google Scholar 

  70. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant. 1998;13(7):1682–5.

    PubMed  CAS  Google Scholar 

  71. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361(22):2153–64.

    PubMed  CAS  Google Scholar 

  72. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright Jr JT, Whelton PK, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(8):936–46.

    PubMed  CAS  Google Scholar 

  73. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA. 1982;248:1465–77.

    Google Scholar 

  74. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47(3):352–8.

    PubMed  CAS  Google Scholar 

  75. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;88:2981–97.

    Google Scholar 

  76. Zamboli P, De Nicola L, Minutolo R, Bertino V, Catapano F, Conte G. Management of hypertension in chronic kidney disease. Curr Hypertens Rep. 2006;8(6):497–501.

    PubMed  CAS  Google Scholar 

  77. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73–87.

    PubMed  CAS  Google Scholar 

  78. The GISEN. Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349: 1857–63.

    Google Scholar 

  79. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351(19): 1952–61.

    PubMed  CAS  Google Scholar 

  80. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12): 861–9.

    PubMed  CAS  Google Scholar 

  81. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–60.

    PubMed  CAS  Google Scholar 

  82. Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, et al. HKVIN Study Group. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47(5):751–60.

    PubMed  CAS  Google Scholar 

  83. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30–48.

    PubMed  Google Scholar 

  84. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156–62.

    PubMed  Google Scholar 

  85. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, et al. African American Study of Hypertension and Kidney Disease Collaborative Research Group. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009;169(17):1587–94.

    PubMed  CAS  Google Scholar 

  86. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3(9):486–92.

    PubMed  CAS  Google Scholar 

  87. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008;51(2):199–211.

    PubMed  Google Scholar 

  88. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):542–51.

    PubMed  CAS  Google Scholar 

  89. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.

    PubMed  CAS  Google Scholar 

  90. Heshka J, Ruzicka M, Hiremath S, McCormick BB. Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy. J Am Soc Hypertens. 2010;4(6):295–301.

    PubMed  Google Scholar 

  91. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433–46.

    PubMed  CAS  Google Scholar 

  92. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. AVOID Study Investigators. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care. 2010;33(11):2304–9.

    PubMed  Google Scholar 

  93. Toto RD. Management of hypertensive chronic kidney disease: role of calcium channel blockers. J Clin Hypertens (Greenwich). 2005;7(4 Suppl 1):15–20.

    CAS  Google Scholar 

  94. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–31.

    PubMed  CAS  Google Scholar 

  95. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70(11):1905–13.

    PubMed  CAS  Google Scholar 

  96. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–36.

    PubMed  CAS  Google Scholar 

  97. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, Babalis D, Böhm M, Coats AJ, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail. 2009;11(9):872–80.

    PubMed  CAS  Google Scholar 

  98. Whaley-Connell A, Habibi J, Johnson M, Tilmon R, Rehmer N, Rehmer J, et al. Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol. 2009;30(4):354–60.

    PubMed  CAS  Google Scholar 

  99. Moore R, Linas S. Endothelin antagonists and resistant hypertension in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19(5):432–6.

    PubMed  CAS  Google Scholar 

  100. Dhaun N, MacIntyre IM, Melville V, et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin: a receptor antagonism in chronic kidney disease. Hypertension. 2009;54:113–9.

    PubMed  CAS  Google Scholar 

  101. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, et al. ASCEND Study Group. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21(3):527–35.

    PubMed  CAS  Google Scholar 

  102. Mori Y, Matsubara H, Nose A, Shibasaki Y, Masaki H, Kosaki A, et al. Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure. Hypertens Res. 2001;24(4):359–63.

    PubMed  CAS  Google Scholar 

  103. Davis BR, Cutler JA, Furberg CD, ALLHAT Collaborative Research Group, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med. 2002;137:313–20.

    PubMed  CAS  Google Scholar 

  104. Mancia G, Parati G, Pomodosi G, et al. Evaluation of the antihypertensive effects of TTS clonidine by multiple 24-hr automatic Blood pressure monitoring. J Cardiovasc Pharmacol. 1987;10(S12):S187–93.

    PubMed  Google Scholar 

  105. Kandler MR, Mah GT, Tejani AM, Stabler SN. Hydralazine for essential hypertension. Cochrane Database Syst Rev. 2010;(8):CD004934.

    Google Scholar 

  106. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino Jr R, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–57.

    PubMed  CAS  Google Scholar 

  107. Gottlieb TB, Katz FH, Chidsey 3rd CA. Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine. Circulation. 1972;45(3):571–82.

    PubMed  CAS  Google Scholar 

  108. Sica DA. Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin Hypertens (Greenwich). 2004;6(5):283–7.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology and Hypertension, Harry S. Truman VA Medical Center, 800 Hospital Dr, Columbia, MO, 65211, USA

    Kunal Chaudhary M.D. & Adam Whaley-Connell

  2. Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, MO, USA

    Kunal Chaudhary M.D., J. P. Buddineni, Joshua Botdorf & Adam Whaley-Connell

Authors
  1. Kunal Chaudhary M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. P. Buddineni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joshua Botdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adam Whaley-Connell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kunal Chaudhary M.D. .

Editor information

Editors and Affiliations

  1. County Hospital, Division of Endocrinology,, SUNY-Downstate and Kings, 450 Clarkson Ave., Brooklyn, 11203, New York, USA

    Samy I. McFarlane

  2. ASH Comprehensive Hypertension Center, Department of Medicine, University of Chicago Medical Center, 5841 S. Maryland Avenue, MC1027, Chicago, 60637, Illinois, USA

    George L. Bakris

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Chaudhary, K., Buddineni, J.P., Botdorf, J., Whaley-Connell, A. (2012). Hypertension in Chronic Kidney Disease. In: McFarlane, S., Bakris, G. (eds) Diabetes and Hypertension. Contemporary Diabetes. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-357-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-357-2_4

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-356-5

  • Online ISBN: 978-1-60327-357-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation